STROBE Statement—checklist of items that should be included in reports of observational studies

Item No.	Recommendation	Page No.	Relevant text from manuscript
1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	A prospective observational study
	(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3	the background and conclusion section in abstract
2	Explain the scientific background and rationale for the investigation being reported	6-7	Line 5-20 in page 6, line 1-8 in page 7
3	State specific objectives, including any prespecified hypotheses	7	Line 9-15 in page 7
4	Present key elements of study design early in the paper		A single-center, prospective, observational study
5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7,10,11	Line 18-23 in page 7(settings, locations and the periods of recruitment) Line 15-22 in page 10, line 1-3 in page 11(exposure, follow-up and data collection)
6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	7,8,10,11	The eligibility criteria were provided in line1-7 in page 8. Patients with snoring who visited our sleep medicine center were collected consecutively. Line 15-22 in page 10, line 1-3 in page 11(the method of follow up)
	2 3 4 5	Recommendation	No. Recommendation No. (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found Explain the scientific background and rationale for the investigation being reported Explain the scientific background and rationale for the investigation being reported Fresent key elements of study design early in the paper Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 7,8,10,11 participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of

Variables	7	unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10	The section of "Sleep study and CPAP treatment", "Definition of BP parameters and grouping" and "Blood sampling for biomarker
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8,9,10	assays" in page 8-10. The data was obtained by questionnaire, cuff measurements, PTT-method, PSG. The details of methods of assessment were provided in page 8,9,10. The same index is measured by the same method.
Bias	9	Describe any efforts to address potential sources of bias	18	A single-center study may have a potential selection bias. The efforts to address the sources of bias were descripted in limitation section(line 15-21 page 18)
Study size	10	Explain how the study size was arrived at	11	A total of 62 patients were needed per treatment group if an error of 0.05 (2-tailed test), a statistical power of 0.9 and a pooled standard deviation of 5.2 (obtained from a pilot study of this sample) were used.

Continued on next page

Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which	11	Continuous variables were
variables		groupings were chosen and why		summarized as mean (SD) or
				median (interquartile range), the
				categorical data was described as
				the absolute value and its
				proportions. The differences
				between the baseline characteristics
				of two subgroups were assessed by
				means of the Student t-test, Mann-
				Whitney U-test or Chi-squared test.
Statistical 12 methods	12	(a) Describe all statistical methods, including those used to control for confounding	11,12	Intergroup differences of the change in BP were established by means of a general linear model adjusted for age, hypersomnolence, sex, smoking and drinking status, the baseline values of BP, BMI, CPAP use and AHI, with the OSA subgroup (low and high BP surge) as a fixed factor.
				Multiple linear regression models were established to explore the factors of BP decrease during CPAP treatment. Age, sex, BMI, baseline BP values, hypersomnolence and CPAP compliance were always entered in the models.
		(b) Describe any methods used to examine subgroups and interactions		None
		(c) Explain how missing data were addressed	11	Multiple imputation method
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	11	Multiple imputation method

		Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy		
		(\underline{e}) Describe any sensitivity analyses	11	Multiple imputation method
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 2	See flowchart
		(b) Give reasons for non-participation at each stage	Figure 2	See flowchart
		(c) Consider use of a flow diagram	Figure 2	See flowchart
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12	Line 11-19 in page 12
		(b) Indicate number of participants with missing data for each variable of interest	Figure 2	See flowchart
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	13,14	A total of 119 patients completed 4- week follow-up, and 25 patients finished 24-month follow-up
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	12,13,14	BPs dropped more markedly in patients in high BP surge group than those in low BP surge group, in both office systolic BP (SBP:5.3 mmHg vs.2.2 mmHg, <i>P</i> =.003) and diastolic BP(DBP:4.0mmHg vs.1.2 mmHg, <i>P</i> <.001), especially the asleep SBP (9.0mmHg vs.2.1 mmHg, <i>P</i> <.001). For 30 cases in the high BP surge group, optimal BP control was achieved in 60.0% of patients and BP <140/90mmHg reached up to 83.3% after 24 months of CPAP. Linear regression revealed that BP index was significantly associated with BP

				decrease during CPAP treatment.
		Case-control study—Report numbers in each exposure category, or summary measures of exposure		
		Cross-sectional study—Report numbers of outcome events or summary measures		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included		See Table 2 and Table 3
		(b) Report category boundaries when continuous variables were categorized	10	After the initial assessment of BP surge profiles in all enrolled subjects, the entire cohort was divided into two groups based on the median BP index (high BP surge group: BP index ≥ 36.2, N=65; low BP surge group: BP index<36.2, N=65) and assigned to optimal CPAP treatment.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		None

Continued on next page

Supplemental material

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.